Ueda T, Dutschman G E, Nair M G, Degraw J I, Sirotnak F M, Cheng Y C
Mol Pharmacol. 1986 Aug;30(2):149-53.
The action of 10-deazaaminopterin, its 10-alkyl derivatives, and their polyglutamates against thymidylate synthase (TMPS) from human acute myeloblastic leukemia was examined. Comparison of aminopterin with methotrexate showed that the methylation of the N10-position (methotrexate) increased the inhibitory effect of aminopterin on TMPS. In contrast, alkylation of the 10-position of 10-deazaaminopterin decreased inhibition of TMPS, and the 50% inhibitory concentration values were progressively higher, in the order 10,10-dimethyl-, 10-methyl-, and 10-ethyl-derivatives. The addition of gamma-glutamyl moieties to both 10-deazaaminopterin, and one of its alkylated analogs, 10-ethyl-10-deazaaminopterin, enhanced inhibition. The maximum inhibition was achieved with the addition of three glutamyl moieties to 10-deazaaminopterin and two glutamyl moieties to 10-ethyl-10-deazaaminopterin, respectively. Thus, 10-deazaaminopterin-tetraglutamate was 138-fold and 10-ethyl-10-deazaaminopterin-triglutamate was greater than 51-fold more active than their respective parental compound. The compounds 10-deazaaminopterin and its polyglutamates, 10-methyl- and 10,10-dimethyl-analogs, inhibited TMPS in a noncompetitive fashion with respect to 5,10-methylene-tetrahydropteroylglutamate. Ki values for the monoglutamates were 220 microM, 310 microM, and 225 microM, respectively. In contrast, 10-ethyl-10-deazaaminopterin and its polyglutamates inhibited TMPS in a competitive fashion with a Ki value of 410 microM for the monoglutamate. With 5,10-methylene-tetrahydropteroylpentaglutamate as a substrate, 10-deazaaminopterin and its polyglutamates behaved as mixed type inhibitors, and 10-ethyl-10-deazaaminopterin, monoglutamate and diglutamate, behaved as noncompetitive inhibitors, whereas its pentaglutamate behaved as a mixed-type inhibitor. These results suggest that the addition of gamma-glutamyl moieties to the substrate also caused the change in the mode of inhibitory action of these compounds. These findings also show that both replacement of the N10-position of the 4-aminopteroyl structure with a methylene group and its alkylation caused interesting and unexpected changes in the structure-activity relationships and the mode of action for these 4-aminopteroyl antifolates as inhibitors of TMPS, which may be therapeutically relevant.
研究了10-脱氮氨基蝶呤、其10-烷基衍生物及其聚谷氨酸盐对人急性髓性白血病胸苷酸合成酶(TMPS)的作用。氨基蝶呤与甲氨蝶呤的比较表明,N10位(甲氨蝶呤)的甲基化增强了氨基蝶呤对TMPS的抑制作用。相反,10-脱氮氨基蝶呤10位的烷基化降低了对TMPS的抑制作用,50%抑制浓度值逐渐升高,顺序为10,10-二甲基-、10-甲基-和10-乙基衍生物。在10-脱氮氨基蝶呤及其一种烷基化类似物10-乙基-10-脱氮氨基蝶呤上添加γ-谷氨酰基部分增强了抑制作用。分别向10-脱氮氨基蝶呤添加三个谷氨酰基部分和向10-乙基-10-脱氮氨基蝶呤添加两个谷氨酰基部分可实现最大抑制。因此,10-脱氮氨基蝶呤四谷氨酸盐的活性比其各自的母体化合物高138倍,10-乙基-10-脱氮氨基蝶呤三谷氨酸盐的活性比其各自的母体化合物高51倍以上。10-脱氮氨基蝶呤及其聚谷氨酸盐、10-甲基-和10,10-二甲基类似物以非竞争性方式抑制TMPS,相对于5,10-亚甲基-四氢蝶酰谷氨酸。单谷氨酸盐的Ki值分别为220μM、310μM和225μM。相反,10-乙基-10-脱氮氨基蝶呤及其聚谷氨酸盐以竞争性方式抑制TMPS,单谷氨酸盐的Ki值为410μM。以5,10-亚甲基-四氢蝶酰五谷氨酸为底物时,10-脱氮氨基蝶呤及其聚谷氨酸盐表现为混合型抑制剂,10-乙基-10-脱氮氨基蝶呤、单谷氨酸盐和二谷氨酸盐表现为非竞争性抑制剂,而其五谷氨酸盐表现为混合型抑制剂。这些结果表明,在底物上添加γ-谷氨酰基部分也导致了这些化合物抑制作用模式的改变。这些发现还表明,用亚甲基取代4-氨基蝶酰结构的N10位及其烷基化都会导致这些4-氨基蝶酰抗叶酸剂作为TMPS抑制剂的构效关系和作用模式发生有趣且意想不到的变化,这可能具有治疗相关性。